CDKN2A and lung cancer: Interestingly, pharmacological inhibition of the DX2–ARF interaction delays tumor growth, suggesting that restoration of ARF in lung cancer can be achieved by manipulation of single pathways, notwithstanding the several factors aiming at its destruction (14).